C. Lu

457 total citations · 1 hit paper
10 papers, 284 citations indexed

About

C. Lu is a scholar working on Oncology, Pharmacology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, C. Lu has authored 10 papers receiving a total of 284 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Oncology, 3 papers in Pharmacology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in C. Lu's work include Pharmacogenetics and Drug Metabolism (3 papers), Hepatocellular Carcinoma Treatment and Prognosis (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). C. Lu is often cited by papers focused on Pharmacogenetics and Drug Metabolism (3 papers), Hepatocellular Carcinoma Treatment and Prognosis (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). C. Lu collaborates with scholars based in United States, China and Japan. C. Lu's co-authors include Albert P. Li, Y Sakai, Roy S. Herbst, Isaiah W. Dimery, P. Fidias, John V. Heymach, Ajit Suri, Sunny Chapel, Karthik Venkatakrishnan and Jaromı́r Roubec and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Pharmacology & Therapeutics and IEEE Transactions on Instrumentation and Measurement.

In The Last Decade

C. Lu

9 papers receiving 274 citations

Hit Papers

Ultra-sensitive pH responsive hydrogels with injectable a... 2025 2026 2025 5 10 15 20
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ultra-sensitive pH responsive hydrogels with injectable and self-healing performance for controlled drug delivery
    2025 24 citations Yang Yu, Yili Zhao et al. International Journal of Pharmaceutics X profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Lu United States 7 114 101 92 49 25 10 284
Carlo Sensenhauser United States 11 140 1.2× 73 0.7× 126 1.4× 21 0.4× 24 1.0× 12 352
Sue Zhou United States 9 197 1.7× 98 1.0× 117 1.3× 12 0.2× 14 0.6× 9 345
Jessica Whritenour United States 9 49 0.4× 33 0.3× 66 0.7× 24 0.5× 15 0.6× 19 290
Takefumi Shimizu Japan 13 111 1.0× 138 1.4× 128 1.4× 13 0.3× 22 0.9× 26 422
Kunihiro Yoshisue Japan 13 242 2.1× 337 3.3× 192 2.1× 95 1.9× 23 0.9× 32 607
Kaori Nakamoto United States 5 160 1.4× 97 1.0× 122 1.3× 10 0.2× 55 2.2× 5 359
Michael J. Dabrowski United States 11 134 1.2× 72 0.7× 198 2.2× 17 0.3× 17 0.7× 20 443
Muriel Saulnier United States 9 55 0.5× 38 0.4× 145 1.6× 52 1.1× 11 0.4× 13 439
Younggil Kwon United States 9 73 0.6× 106 1.0× 148 1.6× 10 0.2× 8 0.3× 11 385
Frederic Moulin United States 8 133 1.2× 37 0.4× 94 1.0× 11 0.2× 61 2.4× 13 362

Countries citing papers authored by C. Lu

Since Specialization
Citations

This map shows the geographic impact of C. Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Lu more than expected).

Fields of papers citing papers by C. Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Lu. The network helps show where C. Lu may publish in the future.

Co-authorship network of co-authors of C. Lu

This figure shows the co-authorship network connecting the top 25 collaborators of C. Lu. A scholar is included among the top collaborators of C. Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Lu. C. Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Yu, Yang, Yili Zhao, Yujiao Zou, et al.. (2025). Ultra-sensitive pH responsive hydrogels with injectable and self-healing performance for controlled drug delivery. International Journal of Pharmaceutics X. 9. 100334–100334. 24 indexed citations breakdown →
2.
Lu, C., et al.. (2024). Recent advances in late‐stage selective deuteration for drug development. Applied Organometallic Chemistry. 38(10). 6 indexed citations
3.
Xia, Xudong, et al.. (2024). Ultrafast and Repeatable Optical Fiber Hydrogen Sensor With Urchin-Like Nanospheres Functionalization. IEEE Transactions on Instrumentation and Measurement. 73. 1–10. 4 indexed citations
4.
Suri, Ajit, Sunny Chapel, C. Lu, & Karthik Venkatakrishnan. (2015). Physiologically based and population PK modeling in optimizing drug development: A predict–learn–confirm analysis. Clinical Pharmacology & Therapeutics. 98(3). 336–344. 21 indexed citations
5.
Heymach, John V., B. E. Johnson, Jacqui Rowbottom, et al.. (2005). A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC. Journal of Clinical Oncology. 23(16_suppl). 3023–3023. 36 indexed citations
6.
Kindler, Hedy L., C. Lu, David R. Gandara, et al.. (2005). A multicenter, double-blind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients (pts) with malignant mesothelioma (MM). Journal of Clinical Oncology. 23(16_suppl). 7019–7019. 7 indexed citations
7.
Heymach, John V., Runyu Dong, Isaiah W. Dimery, et al.. (2004). ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized phase II study. Journal of Clinical Oncology. 22(14_suppl). 3051–3051. 17 indexed citations
8.
Heymach, John V., Runyu Dong, Isaiah W. Dimery, et al.. (2004). ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized phase II study. Journal of Clinical Oncology. 22(14_suppl). 3051–3051. 5 indexed citations
9.
Lu, C., et al.. (2001). Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes.. PubMed. 29(2). 141–4. 164 indexed citations
10.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carlo Sensenhauser Breakdown of academic impact, for papers by Sue Zhou Breakdown of academic impact, for papers by Jessica Whritenour Breakdown of academic impact, for papers by Takefumi Shimizu Breakdown of academic impact, for papers by Kunihiro Yoshisue Breakdown of academic impact, for papers by Kaori Nakamoto Breakdown of academic impact, for papers by Michael J. Dabrowski Breakdown of academic impact, for papers by Muriel Saulnier Breakdown of academic impact, for papers by Younggil Kwon Breakdown of academic impact, for papers by Frederic Moulin
Rankless by CCL
2026